MXPA03003235A - Formulaciones farmaceuticas de liberacion retrasada. - Google Patents

Formulaciones farmaceuticas de liberacion retrasada.

Info

Publication number: MXPA03003235A
Authority: MX; Mexico
Prior art keywords: pharmaceutical formulations; delayed release; release pharmaceutical; delayed; formulations
Prior art date: 2000-10-13

Application number

MXPA03003235A

Other languages

English (en)

Inventor

Derek Allan Prater

Original Assignee

Euro Celtique Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-10-13

Filing date

2001-10-04

Publication date

2003-10-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9901280&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA03003235(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-10-04 Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa

2003-10-15 Publication of MXPA03003235A publication Critical patent/MXPA03003235A/es

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

MXPA03003235A 2000-10-13 2001-10-04 Formulaciones farmaceuticas de liberacion retrasada. MXPA03003235A (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0025208.0A GB0025208D0 (en)	2000-10-13	2000-10-13	Delayed release pharmaceutical formulations
PCT/GB2001/004423 WO2002030398A2 (en)	2000-10-13	2001-10-04	Delayed release pharmaceutical formulations

Publications (1)

Publication Number	Publication Date
MXPA03003235A true MXPA03003235A (es)	2003-10-15

Family

ID=9901280

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MXPA03003235A MXPA03003235A (es)	2000-10-13	2001-10-04	Formulaciones farmaceuticas de liberacion retrasada.

Country Status (13)

Country	Link
US (2)	US20040052846A1 (es)
EP (2)	EP1324752B1 (es)
JP (2)	JP2004510812A (es)
CN (1)	CN1489455B (es)
AU (2)	AU9208601A (es)
BR (2)	BRPI0114633B1 (es)
CA (1)	CA2433186C (es)
DE (1)	DE20121853U1 (es)
DK (1)	DK1324752T3 (es)
GB (1)	GB0025208D0 (es)
IL (2)	IL155293A0 (es)
MX (1)	MXPA03003235A (es)
WO (1)	WO2002030398A2 (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BRPI0206432A2 (pt) *	2001-01-12	2016-10-25	Sun Pharmaceutical Ind Ltd	métodos para administrar dois ou mais agentes terapêuticos ativos e para tratar diabetes melito ou sintomas associados com diabetes melito em um humano e sistema de liberação espaçada de medicamento
WO2002080887A2 (en) *	2001-04-10	2002-10-17	Sun Pharmaceutical Industries Limited	Timed pulse release composition
US7772188B2 (en)	2003-01-28	2010-08-10	Ironwood Pharmaceuticals, Inc.	Methods and compositions for the treatment of gastrointestinal disorders
US20060210633A1 (en) *	2003-04-03	2006-09-21	Sun Pharmaceutical Industries Limited	Programmed drug delivery system
CA2529984C (en)	2003-06-26	2012-09-25	Isa Odidi	Oral multi-functional pharmaceutical capsule preparations of proton pump inhibitors
EP1682537B1 (en)	2003-11-05	2012-03-28	SARcode Bioscience Inc.	Modulators of cellular adhesion
GB0400031D0 (en)	2004-01-03	2004-02-04	Univ Sheffield	Depression treatment
US8394409B2 (en)	2004-07-01	2013-03-12	Intellipharmaceutics Corp.	Controlled extended drug release technology
US10624858B2 (en)	2004-08-23	2020-04-21	Intellipharmaceutics Corp	Controlled release composition using transition coating, and method of preparing same
GB0423964D0 (en) *	2004-10-28	2004-12-01	Jagotec Ag	Dosage form
US20090208579A1 (en) *	2004-12-27	2009-08-20	Eisai R & D Management Co., Ltd.	Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
US20070129402A1 (en) *	2004-12-27	2007-06-07	Eisai Research Institute	Sustained release formulations
US20060280789A1 (en) *	2004-12-27	2006-12-14	Eisai Research Institute	Sustained release formulations
US20060246003A1 (en) *	2004-12-27	2006-11-02	Eisai Co. Ltd.	Composition containing anti-dementia drug
CA2592605C (en) *	2004-12-27	2010-12-07	Eisai R&D Management Co., Ltd.	Method for stabilizing anti-dementia drug
PT1881823E (pt)	2005-05-17	2015-03-02	Sarcode Bioscience Inc	Composições e métodos para o tratamento de transtornos oculares
MY152185A (en) *	2005-06-10	2014-08-29	Novartis Ag	Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
JP4806980B2 (ja) *	2005-06-27	2011-11-02	船井電機株式会社	プロジェクタ用台座
FR2891459B1 (fr) *	2005-09-30	2007-12-28	Flamel Technologies Sa	Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
KR100591142B1 (ko) *	2005-11-04	2006-06-20	지엘팜텍 주식회사	파록세틴을 활성물질로 함유하는 장용성 서방형 정제
US10064828B1 (en)	2005-12-23	2018-09-04	Intellipharmaceutics Corp.	Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
CA2648278C (en) *	2006-04-03	2019-05-28	Isa Odidi	Drug delivery composition
CA2648280C (en)	2006-04-03	2014-03-11	Isa Odidi	Controlled release delivery device comprising an organosol coat
US10960077B2 (en)	2006-05-12	2021-03-30	Intellipharmaceutics Corp.	Abuse and alcohol resistant drug composition
US20080020032A1 (en) *	2006-07-21	2008-01-24	Michael Crowley	Hydrophobic abuse deterrent delivery system for hydromorphone
US20100136125A1 (en) *	2006-12-28	2010-06-03	Jacobus Pharmaceutical Company, Inc.	Method of treating inflammatory bowel disease
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2008151257A2 (en)	2007-06-04	2008-12-11	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US20090036414A1 (en) *	2007-08-02	2009-02-05	Mutual Pharmaceutical Company, Inc.	Mesalamine Formulations
JP2011500553A (ja) *	2007-10-10	2011-01-06	ルピン・リミテッド	５−アミノサリチル酸またはその塩もしくは代謝産物の新規な結腸を標的とする調節放出性生体接着性製剤
MX2010004281A (es)	2007-10-19	2010-09-10	Sarcode Corp	Composiciones y metodos para el tratamiento de la retinopatia diabetica.
PE20091620A1 (es)	2008-03-11	2009-11-12	Takeda Pharmaceutical	Preparacion solida de desintegracion oral
US8080562B2 (en)	2008-04-15	2011-12-20	Sarcode Bioscience Inc.	Crystalline pharmaceutical and methods of preparation and use thereof
WO2009149279A2 (en)	2008-06-04	2009-12-10	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2730603C (en)	2008-07-16	2019-09-24	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2011050175A1 (en)	2009-10-21	2011-04-28	Sarcode Corporation	Crystalline pharmaceutical and methods of preparation and use thereof
JP2011207851A (ja) *	2010-03-30	2011-10-20	Asahi Kasei Chemicals Corp	膨潤性の球状核
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
PL2672981T3 (pl)	2011-02-11	2018-09-28	Zx Pharma, Llc	Wielocząstkowe preparaty l-mentolu i powiązane sposoby
US8808736B2 (en)	2011-02-11	2014-08-19	Zx Pharma, Llc	Enteric coated multiparticulate controlled release peppermint oil composition and related methods
US8911780B2 (en)	2011-02-11	2014-12-16	Zx Pharma, Llc	Multiparticulate L-menthol formulations and related methods
CA2879982C (en)	2012-07-25	2020-09-01	Sarcode Bioscience Inc.	Lfa-1 inhibitor and polymorph thereof
US9545446B2 (en)	2013-02-25	2017-01-17	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase and their uses
EP2970384A1 (en)	2013-03-15	2016-01-20	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase and their uses
WO2014151200A2 (en)	2013-03-15	2014-09-25	Synergy Pharmaceuticals Inc.	Compositions useful for the treatment of gastrointestinal disorders
SMT201900021T1 (it)	2013-04-23	2019-02-28	Zx Pharma Llc	Composizione gastroresistente a base di multiparticolato con sottorivestimento proteinaceo
CN106061494A (zh)	2013-10-10	2016-10-26	辛纳吉制药公司	可用于治疗阿片样物质诱导的功能障碍的鸟苷酸环化酶的激动剂
WO2015061442A1 (en) *	2013-10-22	2015-04-30	Cadila Healthcare Limited	Delayed release pharmaceutical compositions of salsalate
EP3402804A1 (en)	2016-01-11	2018-11-21	Synergy Pharmaceuticals Inc.	Formulations and methods for treating ulcerative colitis
IT201800011120A1 (it) *	2018-12-14	2020-06-14	Dpl Pharma S P A	Composizioni farmaceutiche orali solide per la somministrazione di mesalazina o suoi derivati
JP6578459B1 (ja) *	2019-02-28	2019-09-18	アピ株式会社	ハードカプセル及びその製造方法
US20230045118A1 (en) *	2020-01-17	2023-02-09	Societe Des Produits Nestle S.A.	Dosage form with sustained release melatonin pellets
WO2023215279A1 (en) *	2022-05-03	2023-11-09	Nocion Therapeutics, Inc.	Compositions and methods for treatment of inflammatory bowel disease

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US593697A (en) *		1897-11-16		Electric-arc lamp
EP0061487B1 (de) *	1980-10-07	1985-05-02	KEPLINGER, Klaus	Extract aus Uncaria tomentosa (WILLD.) DC. zur therapeutischen Verwendung
GB8322007D0 (en) *	1983-08-16	1983-09-21	Wellcome Found	Pharmaceutical delivery system
JPH075457B2 (ja) *	1983-08-16	1995-01-25	ザウエルカムフアウンデ−シヨンリミテツド	調節された方法による有効成分の放出を可能にする医薬組成物
CA1239034A (en)	1984-08-17	1988-07-12	Kelly L. Smith	Delivery system
GB8518301D0 (en) *	1985-07-19	1985-08-29	Fujisawa Pharmaceutical Co	Hydrodynamically explosive systems
SE455836B (sv)	1985-10-11	1988-08-15	Haessle Ab	Beredning med kontrollerad frisettning innehallande ett salt av metoprolol samt metod for framstellning av denna beredning
GB8628728D0 (en) *	1986-12-02	1987-01-07	Euro Celtique Sa	Spheroids
JPS63215620A (ja) *	1987-03-03	1988-09-08	Nippon Soda Co Ltd	徐放性製剤
GB8723896D0 (en) *	1987-10-12	1987-11-18	Aps Research Ltd	Controlled-release formulation
US5019397A (en) *	1988-04-21	1991-05-28	Alza Corporation	Aqueous emulsion for pharmaceutical dosage form
GB8913889D0 (en) *	1989-06-16	1989-08-02	May & Baker Ltd	New compositions of matter
US5082669A (en) *	1989-07-20	1992-01-21	Dainippon Pharmaceutical Co., Ltd.	Rapid-releasing oral particle pharmaceutical preparation with unpleasant taste masked
JP3317444B2 (ja) *	1989-07-20	2002-08-26	大日本製薬株式会社	不快な味が遮蔽された速放性製剤
JPH03145418A (ja) *	1989-10-27	1991-06-20	Sumitomo Pharmaceut Co Ltd	塩基性薬物塩酸塩の徐放性製剤
AT397345B (de)	1990-04-04	1994-03-25	Chemiefaser Lenzing Ag	Pharmazeutisches präparat mit verzögerter wirkstofffreisetzung auf basis von hemicellulosen
NZ286242A (en) *	1991-03-26	1997-11-24	Csl Ltd	Use of veterinary implant as a single dose vaccination system: rupturable polymer film coating around core of active agent and water soluble excipient
KR100221695B1 (ko) *	1991-08-12	1999-09-15	그린 마틴, 브라이언 쥐 테슬리	약학적 구상 제형
GB9117361D0 (en) *	1991-08-12	1991-09-25	Euro Celtique Sa	Oral dosage form
JP2861388B2 (ja) *	1991-10-04	1999-02-24	吉富製薬株式会社	徐放性錠剤
GB9407386D0 (en) *	1994-04-14	1994-06-08	Smithkline Beecham Plc	Pharmaceutical formulation
PL179910B1 (pl) *	1994-05-06	2000-11-30	Pfizer	Postac dawkowania o kontrolowanym uwalnianiu zawierajaca azytromycyne PL PL PL PL PL PL PL PL
JPH0826977A (ja)	1994-07-19	1996-01-30	Tanabe Seiyaku Co Ltd	溶出制御型経口製剤
JPH08143476A (ja)	1994-11-18	1996-06-04	Japan Tobacco Inc	薬物放出制御膜及び固形製剤
JP4072597B2 (ja) *	1994-12-27	2008-04-09	ナムローゼ・フェンノートシャップ・オルガノン	持続性製剤
WO1996019974A1 (en) *	1994-12-27	1996-07-04	Kanebo, Ltd.	Sustained-release preparation
US5741818A (en)	1995-06-07	1998-04-21	University Of Saskatchewan	Semicarbazones having CNS activity and pharmaceutical preparations containing same
PE57198A1 (es) *	1996-03-25	1998-10-10	American Home Prod	Formula de liberacion prolongada
US5980942A (en) *	1997-01-23	1999-11-09	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Zero-order sustained release matrix tablet formulations of carbamazepine
DE69829048T2 (de)	1997-04-22	2006-02-09	Euro-Celtique S.A.	Die verwendung von durch carbozyklische und heterozyklische reste substituierte semicarbazonen und thiosemicarbazonen als natriumkanalblocker
JP2000119181A (ja) *	1998-10-06	2000-04-25	Kureha Chem Ind Co Ltd	エスクレチン及びその誘導体の放出制御経口製剤
EP1191924A4 (en)	1999-04-06	2005-02-09	Pharmaquest Ltd	PHARMACEUTICAL DOSAGE FORM FOR INTERMITTENT ADMINISTRATION OF (D-THREO) -METHYLPHENIDATE AND A SECOND STIMULANT OF THE CENTRAL NERVOUS SYSTEM
JP2001055322A (ja)	1999-08-18	2001-02-27	Tanabe Seiyaku Co Ltd	パルス放出型製剤
US9050326B2 (en)	2008-04-02	2015-06-09	Astellas Pharma Inc.	Amido derivatives-contained pharmaceutical composition

2000
- 2000-10-13 GB GBGB0025208.0A patent/GB0025208D0/en not_active Ceased
2001
- 2001-10-04 IL IL15529301A patent/IL155293A0/xx unknown
- 2001-10-04 BR BRPI0114633-5A patent/BRPI0114633B1/pt unknown
- 2001-10-04 EP EP01972310.5A patent/EP1324752B1/en not_active Expired - Lifetime
- 2001-10-04 AU AU9208601A patent/AU9208601A/xx active Pending
- 2001-10-04 EP EP10010916A patent/EP2263656A1/en not_active Ceased
- 2001-10-04 BR BR0114633-5A patent/BR0114633A/pt not_active IP Right Cessation
- 2001-10-04 AU AU2001292086A patent/AU2001292086B2/en not_active Ceased
- 2001-10-04 WO PCT/GB2001/004423 patent/WO2002030398A2/en not_active Ceased
- 2001-10-04 CN CN018202772A patent/CN1489455B/zh not_active Expired - Fee Related
- 2001-10-04 JP JP2002533841A patent/JP2004510812A/ja active Pending
- 2001-10-04 CA CA2433186A patent/CA2433186C/en not_active Expired - Fee Related
- 2001-10-04 DK DK01972310.5T patent/DK1324752T3/en active
- 2001-10-04 MX MXPA03003235A patent/MXPA03003235A/es active IP Right Grant
- 2001-10-04 US US10/399,077 patent/US20040052846A1/en not_active Abandoned
- 2001-10-04 DE DE20121853U patent/DE20121853U1/de not_active Expired - Lifetime
2003
- 2003-04-08 IL IL155293A patent/IL155293A/en active IP Right Grant
2006
- 2006-11-22 US US11/603,766 patent/US10231936B2/en not_active Expired - Fee Related
2010
- 2010-01-29 JP JP2010034051A patent/JP5501020B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
WO2002030398A3 (en)	2003-03-13
EP2263656A1 (en)	2010-12-22
CA2433186C (en)	2011-04-26
GB0025208D0 (en)	2000-11-29
CN1489455A (zh)	2004-04-14
US10231936B2 (en)	2019-03-19
IL155293A (en)	2015-11-30
DE20121853U1 (de)	2003-07-31
CN1489455B (zh)	2010-05-26
AU9208601A (en)	2002-04-22
IL155293A0 (en)	2003-11-23
BRPI0114633B1 (pt)	2017-06-20
US20070071820A1 (en)	2007-03-29
JP2010150271A (ja)	2010-07-08
EP1324752A2 (en)	2003-07-09
JP5501020B2 (ja)	2014-05-21
WO2002030398A2 (en)	2002-04-18
EP1324752B1 (en)	2016-04-06
US20040052846A1 (en)	2004-03-18
AU2001292086B2 (en)	2007-06-07
CA2433186A1 (en)	2002-04-18
DK1324752T3 (en)	2016-07-25
BR0114633A (pt)	2004-02-10
JP2004510812A (ja)	2004-04-08

Publication	Publication Date	Title
MXPA03003235A (es)	2003-10-15	Formulaciones farmaceuticas de liberacion retrasada.
ZA200003997B (en)	2000-08-14	Pharmaceutical compositions.
MXPA03007215A (es)	2003-12-04	Formulaciones farmaceuticas.
EG24742A (en)	2010-07-14	Vaccine composition.
MXPA03000771A (es)	2003-06-04	Nuevas composiciones farmaceuticas.
EP1383376A4 (en)	2006-03-08	PHARMACEUTICAL FORMULATIONS WITH PROLONGED RELEASE
ZA200200743B (en)	2003-06-25	Preserved pharmaceutical formulations.
AU2002229140A1 (en)	2002-02-18	Controlled release pharmaceutical composition
ZA200101012B (en)	2002-08-06	Pharmaceutical combinations.
MXPA01012478A (es)	2003-10-14	Formulaciones farmaceuticas mejoradas.
ZA200210359B (en)	2003-11-13	Pharmaceutical compositions.
GB0025473D0 (en)	2000-11-29	Pharmaceutical combinations
MXPA03002569A (es)	2003-10-14	Formulaciones de liberacion controlada para administracion oral.
HUP0301177A3 (en)	2006-07-28	Ion-strength independent sustained release pharmaceutical formulation
GB0020691D0 (en)	2000-10-11	Pharmaceutical combination
MXPA03002105A (es)	2003-06-19	Composiciones farmaceuticas.
GB0012291D0 (en)	2000-07-12	Pharmaceutical combination
GB0005382D0 (en)	2000-04-26	Pharmaceutical composition
GB0012293D0 (en)	2000-07-12	Pharmaceutical combination
GB0021487D0 (en)	2000-10-18	Pharmaceutical
ZA200104935B (en)	2002-12-11	Extended release buccal tablet.
GB0016426D0 (en)	2000-08-23	Pharmaceutical combination
GB0017666D0 (en)	2000-09-06	Pharmaceutical combination
GB0002691D0 (en)	2000-03-29	Pharmaceutical composition
ZA200303911B (en)	2004-04-01	Medicinal compositions.

Legal Events

Date	Code	Title	Description
2008-02-11	FG	Grant or registration